This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
Mazdutide
Dual GLP-1/Glucagon Receptor Agonist (Oxyntomodulin Analog)
/WHAT_IT_IS
Mazdutide (IBI362 / LY3305677) is a once-weekly peptide dual agonist of the GLP-1 receptor and glucagon receptor, derived from the oxyntomodulin scaffold and engineered for prolonged half-life and potent metabolic effects.
/USAGE
Studied for chronic weight management and metabolic health, including reductions in body weight, waist circumference, liver fat, and improvements in glycemic and cardiometabolic markers.
/MECHANISM_OF_ACTION
Co-activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, while GCGR activation increases energy expenditure and promotes lipid mobilization; the combined signaling yields greater weight loss vs. GLP-1–only agonism in studies.
Reported Benefits
- +Clinically meaningful body-weight reduction
- +Appetite suppression and improved satiety
- +Improved glycemic control and cardiometabolic markers
- +Reductions in liver fat and waist circumference in trials
Reported Side Effects
- −Class-typical GI effects (nausea, vomiting, diarrhea/constipation)
- −Decreased appetite
- −Injection-site reactions
- −Transient increases in pancreatic enzymes (e.g., lipase) reported
- −Rare: gallbladder disease or pancreatitis (GLP-1 class consideration)
/STACKED_WITH
/RESEARCH_NOTES
Phase 3 data in adults with overweight/obesity demonstrated significant weight loss at 4 mg and 6 mg once weekly; approved in China (June 2025) for chronic weight management. Monitor GI tolerability and pancreatic enzymes; consider gallbladder risk typical of incretin-based therapies.
/REFERENCE
https://pubmed.ncbi.nlm.nih.gov/40421736//RELATED
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.